← Back to Search

Somatostatin Analog

IONIS GHR-LRx for Acromegaly

Phase 2
Waitlist Available
Research Sponsored by Ionis Pharmaceuticals, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Randomized in index trial (CS2) and completed the entire study, or completion of the treatment period for CS2 and completed or plan to complete PTWK5 visit with an acceptable safety profile, per investigator judgment
Participants with confirmed stable monthly regimen of SRL for 3 months prior to screening
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to approximately 16 months
Awards & highlights

Study Summary

This study is evaluating whether extended dosing with a growth hormone receptor antagonist can improve symptoms in people with acromegaly.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to approximately 16 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to approximately 16 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
The Incidence of Adverse Events
Secondary outcome measures
Percent Change from Baselines in Insulin-like Growth Factor I (IGF-1) Levels
Percentage of Participants who Achieve Normalized IGF-1 Levels to Within 1.0 Times of Gender and Age-Adjusted Upper Limits
Percentage of Participants who Achieve Normalized IGF-1 Levels to Within 1.2 Times of Gender and Age-Adjusted Upper Limits
+2 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: IONIS GHR-LRx + Somatostatin Receptor Ligand (SRL)Experimental Treatment2 Interventions
IONIS GHR-LRx (as per dose in previous study) will be administered subcutaneously once every 28 days for 53 weeks.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
IONIS GHR-LRx
2019
Completed Phase 2
~40
Somatostatin Receptor Ligand (SRL)
2019
Completed Phase 2
~40

Find a Location

Who is running the clinical trial?

Ionis Pharmaceuticals, Inc.Lead Sponsor
145 Previous Clinical Trials
15,226 Total Patients Enrolled
2 Trials studying Acromegaly
77 Patients Enrolled for Acromegaly

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~7 spots leftby Mar 2025